Gut Microbiome in Pulmonary Arterial Hypertension-An Emerging Frontier

Area of Science:

• Gastroenterology and Immunology
• Cardiology
• Microbiology

Background:

• Pulmonary arterial hypertension (PAH) is a severe condition leading to right ventricular failure.
• Current treatments for PAH lack sufficient efficacy, highlighting the need for novel adjunctive therapies.
• The gut microbiome's role in modulating immune responses presents a potential therapeutic avenue for PAH.

Purpose of the Study:

• To review the evidence linking gut dysbiosis to PAH.
• To explore the potential of targeting the gut microbiome as a treatment strategy for PAH.
• To discuss challenges in translating microbiome research into clinical applications for PAH.

Main Methods:

• Review of preclinical and clinical studies on gut microbiome alterations in PAH.
• Analysis of mechanisms by which gut dysbiosis may influence PAH pathogenesis.
• Examination of strategies for microbiome modulation and their clinical applicability.

Main Results:

• Emerging evidence indicates significant gut dysbiosis in PAH patients.
• Alterations in the gut microbiome may initiate or exacerbate PAH by affecting systemic immunity.
• Infections have also been implicated in PAH development and progression.

Conclusions:

• Gut dysbiosis is a significant factor in PAH pathogenesis and progression.
• Targeting the gut microbiome offers a promising adjunctive therapy approach for PAH.
• Further research is needed to elucidate mechanisms and overcome clinical translation challenges.